Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of 20-valent pneumococcal conjugate vaccine in infants using a 2+1 schedule
NL-OMON49743Phase 3Completed
- Sponsor
- Pfizer
- Start
- Apr 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Prevnar 20 in pneumococcal disease (2 arms), sponsored by Pfizer. Primary endpoints: Safety profile of 20vPnC, Primary concomitant immunogenicity noninferiority and 4 more. Started Apr 2021; status: completed.
02
Drugs
Prevnar 20
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NL-OMON49743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49743.